BHC Filings — Bausch Health Companies Inc. - FilingSpy
BHC
Bausch Health Companies Inc.
A Canadian healthcare company behind some of the world's best-known eye and skin products, Bausch Health makes contact lenses, dry-eye treatments, and the Thermage skin-tightening device, while its Salix arm sells the gut medicine Xifaxan. Its roots trace to an 1853 Rochester optical shop founded by John Jacob Bausch, who borrowed money from friend Henry Lomb to get the business going. The company began as ICN Pharmaceuticals in 1959 and later renamed itself after the famous lens maker it acquired — the firm that brought America its first mass-produced soft contact lenses in 1971.
Bausch Health director Michael Goettler resigns effective June 30, 2026, to become CEO of Knoa Pharma LLC.
The resignation is in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
Show detailsHide details
Michael Goettler notified Bausch Health of his resignation from the Board of Directors on June 26, 2026, effective June 30, 2026.
The company stated the resignation was not due to any disagreement with Bausch Health on operations, policies, or practices.
A press release dated July 1, 2026, announcing the resignation was furnished as Exhibit 99.1.
John A. Paulson, Chairperson of the Board, thanked Goettler for his service and wished him well.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
Bausch Health shareholders elect 10 directors, approve executive pay and PwC as auditor at 2026 annual meeting
At the May 19, 2026 Annual Meeting, shareholders elected 10 directors, including new director Eiry W. Roberts, M.D., each to serve until the 2027 annual meeting.
Show detailsHide details
All director nominees received majority support, with votes for ranging from 183,885,617 (Frank D. Lee) to 196,972,752 (Eiry W. Roberts); broker non-votes were 79,859,606 for each.
Shareholders approved, on a non-binding advisory basis, executive compensation for Named Executive Officers: 189,432,400 for, 9,588,417 against, 537,614 abstain.
Shareholders appointed PricewaterhouseCoopers LLP as independent auditor until the 2027 annual meeting, with 276,774,936 votes for and 2,643,100 withheld.
The report was filed under Item 5.07 to disclose the results of the three shareholder votes at the annual meeting.
5.07 Submission of Matters to a Vote of Security Holders
Bausch Health Q1 2026 revenue up 12% to $2.52B, but net loss widens on $1.43B goodwill impairment
First quarter 2026 consolidated revenues were $2.52 billion, up 12% reported and 7% organic year-over-year.
Show detailsHide details
GAAP net loss attributable to Bausch Health was $1,423 million, including a $1,426 million goodwill impairment charge related to Salix's RED-C program.
Adjusted earnings per diluted share (non-GAAP) rose 32% to $0.78 from $0.59 in the prior year period.
Consolidated Adjusted EBITDA attributable to Bausch Health (non-GAAP) was $837 million, up 27% year-over-year.
Company reaffirmed full-year 2026 guidance for Bausch Health excluding Bausch + Lomb, and updated consolidated revenue and Adjusted EBITDA guidance.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Bausch Health to pay 2023 PSUs in cash instead of stock for two executives
On February 26, 2026, Bausch Health amended the 2023 PSU award agreement for CEO Thomas Appio to settle 1,137,862 PSUs in cash at the market price on the March 3, 2026 vesting date.
Show detailsHide details
The company entered into a separate agreement with Seana Carson to surrender her 137,922 2023 PSUs for cash at the same market price, as contemplated by Canadian tax law.
The 2023 PSUs were originally granted in March 2023 and earned over a three-year performance period.
The cash settlement amount will be based on the closing price of Bausch Health common stock on the vesting date.
The full agreements will be filed with the Form 10-Q for the quarter ending March 31, 2026.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Bausch Health's Phase 3 RED-C trials for hepatic encephalopathy miss primary endpoint
Bausch Health announced results of the global Phase 3 RED-C clinical program evaluating amorphous-rifaximin SSD in adults with liver cirrhosis for primary prevention of hepatic encephalopathy.
Show detailsHide details
Both clinical trials did not meet the primary endpoint, though the treatment was safe and well-tolerated.
The program involved more than 1,000 patients across 398 sites in 17 countries.
CEO Thomas J. Appio stated the company is reviewing the full dataset to determine potential new development opportunities.
The results were disclosed via press release on January 23, 2026, under Item 7.01 Regulation FD Disclosure.